CAS 132810-10-7
:Blonanserina
- 2-(4-Ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine
- 2-(4-Ethyl-1-piperazinyl)-4-(p-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta(b)pyridine
- 2-(4-Ethylpiperazin-1-Yl)-4-(4-Fluorophenyl)-5,6,7,8,9,10-Hexahydrocycloocta[B]Pyridine
- Ad 5423
- Cycloocta(b)pyridine, 2-(4-ethyl-1-piperazinyl)-4-(1-fluorophenyl)-5,6,7,8,9,10-hexahydro-
- Cycloocta(b)pyridine, 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydro-
- Lonasen
- Blonanserin
Blonanserin
CAS:Fórmula:C23H30FN3Pureza:>98.0%(HPLC)Forma y color:White to Almost white powder to crystalPeso molecular:367.51Blonanserin
CAS:Blonanserin (AD-5423), approved in Japan (2008), is an atypical antipsychotic with fewer side effects like EPS, sedation, or hypotension.Fórmula:C23H30FN3Pureza:99.85% - 99.99%Forma y color:SolidPeso molecular:367.50Cycloocta[b]pyridine, 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydro-
CAS:Fórmula:C23H30FN3Pureza:98.0%Forma y color:SolidPeso molecular:367.5028Blonanserin (Standard)
CAS:Blonanserin (Standard) is a reference standard for research and analysis in studies involving Blonanserin. Blonanserin (AD-5423) is an atypical antipsychotic approved in Japan in January, 2008. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension.Fórmula:C23H30FN3Peso molecular:367.50Blonanserin
CAS:Producto controladoApplications A 5-HT2 serotonin receptor and D2 dopamine receptor antagonist, used as an antipsychotic.
References Oka, T., et al.: Life Sci., 76, 225 (2004), Singh, A., et al.: Int. Med. J., 12, 175 (2005), Ochi, T., et al.: Bioorg. Med. Chem., Lett., 15, 1055 (2005),Fórmula:C23H30FN3Forma y color:NeatPeso molecular:367.5Blonanserin
CAS:Producto controladoBlonanserin is a drug for the treatment of congestive heart failure. It is a potent and selective antagonist of 5-HT2A receptors. Blonanserin was shown to increase serum prolactin levels in humans, and has been shown to decrease locomotor activity in rats. The effects on locomotor activity are not due to its effect on dopamine or serotonin levels, but may be caused by its matrix effect on 5-HT2A receptors. The long-term efficacy of blonanserin has been demonstrated by the fact that it can be used as a pharmacological treatment for Parkinson's disease and schizophrenia.
Fórmula:C23H30FN3Pureza:Min. 95%Peso molecular:367.5 g/mol








